We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
+47.09%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$34M
Cap. Flow
-$6.07M
Cap. Flow %
-2.82%
Top 10 Hldgs %
99.27%
Holding
13
New
–
Increased
–
Reduced
–
Closed
1
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.9 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$6.07M

Sector Composition

Rank Sector Weight
1 Healthcare 62.76%
2 Miscellaneous 37.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RNA icon
1
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$78.4M 36.44%
6,213,924
– –
2013 Q3
3 quarters
SUPN icon
2
DELISTED
Supernus Pharmaceuticals
SUPN
$39.3M 18.28%
3,600,000
– –
2013 Q2
4 quarters
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$36.2M 16.83%
1,240,912
– –
2013 Q2
4 quarters
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$26.7M 12.4%
1,182,196
– –
2014 Q1
1 quarter
AMRN icon
5
Amarin Corp
AMRN
$492M
$14.2M 6.58%
404,374
– –
2013 Q2
4 quarters
CEMP
6
DELISTED
Cempra, Inc.
CEMP
$7.65M 3.55%
714,285
– –
2013 Q2
4 quarters
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$4.67M 2.17%
291,902
– –
2013 Q2
4 quarters
RGLS icon
8
DELISTED
Regulus Therapeutics
RGLS
$2.62M 1.22%
2,728
– –
2014 Q1
1 quarter
ACHV icon
9
Achieve Life Sciences
ACHV
$2.23M 1.04%
274
– –
2013 Q2
4 quarters
HPTX
10
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.63M 0.76%
62,500
– –
2013 Q2
4 quarters
ANTH
11
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.48M 0.69%
54,749
– –
2013 Q2
4 quarters
ZLCS
12
DELISTED
ZALICUS INC COM NEW
ZLCS
$96K 0.04%
78,966
– –
2013 Q2
4 quarters
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-102,200
Closed -$6.07M –

Similar funds

Arabesque Asset Management
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
Equius Partners
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
Mass Ave Global
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
August Capital Management VII
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2014 Portfolio in Review

As of Q2 2014, Abingworth held 13 positions worth $215M, up 19% from $181M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Abingworth's Q2 2014 filing shows 1 closed position. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $6.07M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 80% a quarter earlier, followed by Miscellaneous.

  • Abingworth fully exited GW Pharmaceuticals Plc American Depositary Shares in Q2 2014, selling an estimated $6.07M.
  • Abingworth's ten largest holdings make up 99% of its $215M portfolio in Q2 2014.
  • Abingworth opened 0 new positions and closed 1 in Q2 2014.
  • Abingworth's portfolio value rose 19% quarter-over-quarter to $215M.

Based on Abingworth's 13F filing for Q2 2014, filed 14 Aug 2014.